Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bacopa Monnieri wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
4 of 4 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Bacopa Monnieri and Oxiracetam have evidence — compare verdict strength side-by-side.
300-450mg daily (standardized to 50% bacosides)
With fatty meal for absorption
Bacognize® or Synapsa® standardized extract
800-2400mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, With choline source
Oxiracetam powder or capsules
8-12 weeks
8-12 weeks
First 2 weeks
First week
1-2 weeks
1-2 weeks
1-2 weeks
If choline-deficient
Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review
Nutrients (2025) · Systematic review
The evidence revealed the potential use of supplements as complementary ADHD treatments under clinical guidance.
Effectiveness of Bacopa Monnieri (Brahmi) in the management of schizophrenia: a systematic review
Nutritional neuroscience (2025) · Systematic review · n=103
Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population.
Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability
Nutrients (2025) · Systematic review
Animal studies have shown promising results in reducing symptoms and protecting against neurodegeneration.
Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment
Pakistan journal of pharmaceutical sciences (2020) · Rct · n=120
The combined group had the highest effective rate and the total effective rate was 93.3%.
A Meta-Analysis of Au/Polypropionic Acid Nanoparticles Loaded with Olacetam for the Treatment of Vascular Cognitive Impairment
Journal of nanoscience and nanotechnology (2020) · Meta analysis
The results of the meta-analysis showed that compared with placebo and other medications, oxiracetam significantly improved the mental status of patients, Concise Mental State Checklist score [mean difference (MD)= 5.29, P < 0.01] and Montreal Cognitive Assessment score (MD = 4.32, P < 0.01).
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Based on meta-analysis of 437 participants showing improvements in attention, processing speed, and working memory. However, one large RCT (n=101) found no significant between-group differences. Effects may take 8-12 weeks to manifest. Standardized extracts (Bacognize, Synapsa) may have better bioavailability than generic forms.
Based on multiple meta-analyses showing cognitive improvements in vascular dementia and stroke populations. One major RCT (n=500) showed no benefit for post-stroke cognitive impairment, limiting confidence. Effects may be population-specific and less pronounced in healthy individuals.
AI-estimated from published studies. Interpret as directional guidance.
Bacopa Monnieri has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For improve memory & learning, Bacopa Monnieri has a higher relevance score (95 vs 62).
No known interactions between Bacopa Monnieri and Oxiracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.